top of page

COR-L23/R Drug Resistance Cell

Item
Cat#
Price

Drug Resistance Cell

SNB-TC-0145

Inquiry

Compound Test Services

CT-002

Inquiry


Product Description


The cell line COR-L23/R is a multi-drug resistant (MDR) sub-line derived from the parent line COR-L23 after treatment with doxorubicin (adriamycin). The P-glycoprotein negative cell line is cross resistant to daunorubicin, vincristine and rhodamine 123. COR-L23/R contain reduced levels of glutathione and glutathione-S-transferase activity compared to the parent line.


Screeningbio‘s COR-L23/R resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.

Data

Proliferation Assay. COR-L23 and COR-L23/R cell were seed at 384 well for 7 days proliferation assay. Doxorubicin were titrated for 11 point dose, 2 fold dilution. After 7 days compound treatment, cell were tested by CellTiter Glo reagent for viability test. Non-linear regression was used to plot viability changes vs. [Compound, nM], and IC50 values were determined, using GraphPad Prism software.
Proliferation Assay. COR-L23 and COR-L23/R cell were seed at 384 well for 7 days proliferation assay. Doxorubicin were titrated for 11 point dose, 2 fold dilution. After 7 days compound treatment, cell were tested by CellTiter Glo reagent for viability test. Non-linear regression was used to plot viability changes vs. [Compound, nM], and IC50 values were determined, using GraphPad Prism software.



Target Background


The cell line COR-L23/R is a multi-drug resistant (MDR) sub-line derived from the parent line COR-L23 after treatment with doxorubicin (adriamycin). The P-glycoprotein negative cell line is cross resistant to daunorubicin, vincristine and rhodamine 123. COR-L23/R contain reduced levels of glutathione and glutathione-S-transferase activity compared to the parent line.


Screeningbio‘s COR-L23/R resistance cell line generated by exposing to increasing concentration of drug for certain period of time. After stable acquire resistance, cells were harvested and characterized for drug resistance by 7 days proliferation assay.






Product Documentation



Related Products


bottom of page